KRAS promotes the initiation of tumor growth and ensures tumor progression by stimulating tumor-associated angiogenesis [121,122] and activating different effector pathways through the upregulation of VEGF (vascular endothelial growth factor) and CXC chemokine interleukin-8 (IL-8) [121,123,124,125,126]. The gene discussed is CXCL8; the disease is neoplasm.